<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation for infection before solid organ transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation for infection before solid organ transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation for infection before solid organ transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jay A Fishman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Solid organ transplantation is the therapy of choice for a variety of types of organ failure. Two major complications, infection and malignancy, are the result of the life-long immunosuppression needed to maintain allograft function. </p><p>The pretransplant evaluation identifies the risks of the transplant candidate for post-transplant infections and defines individualized preventative strategies including treatment of existing infections, prophylaxis, and vaccination. Thus, the evaluation focuses on exposure history, prior infections, serologic testing for distant exposures, cultures to identify colonization patterns, and administration of vaccines [<a href="#rid1">1</a>]. Active infections are also assessed close to the time of transplantation including HIV, hepatitis B and C, and severe acute respiratory syndrome coronavirus 2.</p><p>The components of the pretransplant evaluation will be reviewed here. The infections that follow solid organ transplantation are discussed in the following topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"</a>.)</p><p></p><p class="headingAnchor" id="H58202540"><span class="h1">CAUSES OF INFECTION</span><span class="headingEndMark"> — </span>The organisms commonly associated with post-transplant infection are the result of reactivation of latent infection carried by the donor organ or the recipient and/or following new exposures in the community or in the hospital [<a href="#rid1">1-4</a>]. Latent infection refers to organisms present in the intended recipient or in the donor tissue that are not causing disease. Cytomegalovirus, Epstein-Barr virus, <em>Toxoplasma gondii</em>, <em>Strongyloides stercoralis</em>, and <em>Trypanosoma cruzi</em> are examples of organisms that can exist in normal hosts and are, in general, controlled by the immune system. The risk for reactivation (replication) of such latent infections is related to the nature and intensity of the immune suppression following transplantation [<a href="#rid5">5</a>].</p><p>Established infection is more difficult to treat in the immunocompromised transplant recipient. Significant antimicrobial toxicities are common, often due to diminished renal or hepatic function and drug interactions. Thus, a pretransplant evaluation for infection is central to care and should be comprehensive. The evaluation targets:</p><p class="bulletIndent1"><span class="glyph">●</span>Identification and treatment of any active infection prior to transplantation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of latent infections and a prophylactic strategy to prevent reactivation following transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of pertinent colonization with multidrug-resistant organisms (MDROs) as a basis for perioperative antimicrobial management</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gaps in vaccine-preventable infections, notably those requiring live vaccines or series of vaccinations (eg, measles, mumps, and rubella or hepatitis B virus)</p><p></p><p>Colonizing organisms are potential pathogens in the setting of immune suppression or acutely in the postoperative setting if acquired from the environment via vascular access catheters, endotracheal tubes, anastomotic leaks, fluid collections, or open surgical wounds [<a href="#rid6">6-9</a>]. Infections, when they occur, may manifest well after transplantation. Colonizing organisms may include antimicrobial-resistant organisms such as <em>Pseudomonas aeruginosa</em>, <em>Aspergillus</em> species, <em>Stenotrophomonas maltophilia</em>, <em>Burkholderia cepacia</em>, methicillin-resistant <em>Staphylococcus aureus</em>, and vancomycin-resistant enterococci. Colonization with such resistant pathogens is common with:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple prior hospitalizations</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple exposures to broad-spectrum antimicrobial agents</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis or other forms of chronic lung disease</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiomyopathy with heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis often with ascites</p><p class="bulletIndent1"><span class="glyph">●</span>Those awaiting organ replacement with chronic organ dysfunction</p><p></p><p>MDROs including carbapenem-resistant <em>Klebsiella pneumoniae</em> and other gram-negative bacilli are increasingly common in solid organ transplant recipients [<a href="#rid3">3,7,9-11</a>]<em>.</em> The identification of such potential pathogens prior to transplantation allows perioperative prophylaxis and/or appropriate antimicrobial therapy if infection occurs. There is no consensus regarding optimal approaches to screening for MDROs prior to transplantation. Antimicrobial therapy should be based on in vitro susceptibility data and accompanied by debridement of foci of infections, such as infected hematoma or other fluid collections.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL EVALUATION</span><span class="headingEndMark"> — </span>The clinical evaluation of a patient prior to solid organ transplantation should focus on exposure history, history of prior infections, cultures for colonization, serologies for more distant exposures, and administration of vaccines [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">History</span><span class="headingEndMark"> — </span>Important elements of the pretransplant historical evaluation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Travel to or residence in areas of the world with unique endemic infections (eg, <em>S. stercoralis</em>, <em>Trypanosoma </em>spp, <em>Schistosoma </em>spp, <em>Leishmania </em>spp, <em>Histoplasma capsulatum</em>, <em>Coccidioides </em>spp, <em>Paracoccidioides </em>spp, <em>Brucella </em>spp, hepatitis viruses, mycobacteria infections)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travel to or residence in areas with outbreaks of infection (eg, West Nile Virus, Zika virus, coronavirus disease 2019 [COVID-19], flooding after hurricanes)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Animal exposures including cats, dogs, rodents, or birds</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary exposures including well water, unpasteurized dairy products, or imported cheeses (eg, <em>Cryptosporidium</em> or <em>Listeria monocytogenes</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Employment and hobbies including exposures to soil, birds, and toxins (endemic fungi, nontuberculous mycobacteria)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential or known exposure to tuberculosis (TB) and/or prior testing for TB</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for HIV infection and other sexually transmitted infections</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential or known exposure to hepatitis viruses</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of prosthetic material (eg, prosthetic joint, central venous catheters, pacemakers)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other active infections, prior infections, and conditions that may predispose to infection (eg, urinary tract infections, vesicoureteral reflux, herpes simplex infections, shingles, recurrent respiratory tract infections, diverticulitis, cholecystitis, hepatitis, peritonitis, tick bites, <em>Salmonella</em> or <em>Toxoplasma </em>infections)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical history (eg, splenectomy, sinus surgery, portasystemic shunting)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac valvular abnormalities or vascular defects (aneurysms) or clots</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies, particularly those infectious in origin which can reactivate post-transplant (eg, anogenital carcinoma due to papilloma virus, nasopharyngeal carcinoma, or Burkitt lymphoma associated with Epstein-Barr virus)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug and alcohol use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaccination history</p><p></p><p>A thorough history of immunosuppressive therapies is essential. Use of immunosuppressive therapies in the pretransplant period can increase the risk of <em>Pneumocystis jirovecii</em> pneumonia, reactivation of TB, hepatitis B virus, histoplasmosis, cryptococcosis, or toxoplasmosis in the early post-transplant period. In addition, a history of recent immunosuppressive regimens such as glucocorticoids for systemic lupus erythematosus or chronic obstructive pulmonary disease, T cell or B cell depletion and immune modulators ("biologics") for rheumatologic disease or inflammatory bowel disease, or past treatment for malignancy can alter the choice and intensity of both prophylactic and immunosuppressive regimens after transplantation.</p><p>A careful review of systems should be performed to uncover current occult infection or colonization. All prior infections should be documented, including the antimicrobial susceptibility pattern of organisms previously isolated and any treatments received. In some cases, transplant candidates with recurrent infections such as cholecystitis, sinusitis, diverticulitis, and pyelonephritis may need to have these conditions resolved prior to transplantation.</p><p class="headingAnchor" id="H4"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing for evidence of past infectious exposures or active infections is performed to determine the risk for infection in the transplant recipient [<a href="#rid1">1-3,12,13</a>]. Some tests are suggested for all patients, whereas others are useful in selected patients with suggestive epidemiologic risk factors  (<a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">table 1</a>).</p><p>Serologic testing is used as an indicator of prior infections. Antibody-based tests (serologic tests) should not, in general, be used for the diagnosis of active infections since there may be a delay between pathogen exposure and seroconversion ("window period"). Nucleic acid amplification tests are used to detect and measure active infections in organ donors or recipients and generally will be positive earlier in infection compared with serologic assays.</p><p>Screening serologies for cytomegalovirus, herpes simplex virus, <em>T. gondii</em>, <em>H. capsulatum</em>, <em>Coccidioides </em>spp, and <em>T. cruzi</em> (Chagas disease) are used as guides for prophylactic strategies after transplantation rather than for pretransplant therapies. Other tests indicate needed (re-)vaccinations including hepatitis B virus, varicella zoster, measles, mumps, and rubella, diphtheria, pertussis, and tetanus. Epstein-Barr virus serologies are useful in stratifying the risk for post-transplant lymphoproliferative disorders, particularly among pediatric recipients and those treated with <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> who are at higher risk [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/7300.html" rel="external">"Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant patients"</a> and  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p><em>Histoplasma</em> and <em>Coccidioides</em> antibodies are insensitive for detecting latent infections. Therefore, negative serologies do not rule out latent infections with these pathogens. The risk of infection should be assessed for each patient based upon exposure history, reports of prior consistent symptomatic infections (eg, Valley fever), and findings of healed granulomas (eg, in the lungs and/or hilar lymph nodes), suggesting latent infection.</p><p>Viral load testing should be obtained for HIV, hepatitis B virus, and hepatitis C virus in infected candidates. Routine peritransplant prophylaxis for hepatitis B is advocated for unvaccinated liver transplant recipients with active infections. Decisions regarding the timing of hepatitis C virus therapy should be individualized based on disease activity and likely waiting time for liver transplantation. (See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7354.html" rel="external">"Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients"</a>.)</p><p>Particular note must be made of TB testing (See <a class="local">'Testing for latent tuberculosis'</a> below.)</p><p>Patients with positive serologies for <em>Strongyloides </em>should be treated prior to transplantation. Empiric treatment (with or without serologic testing) for patients with possible prior exposure (eg, residence in an endemic area) is also common practice [<a href="#rid14">14</a>]. <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">Ivermectin</a> is the treatment of choice. </p><p>In endemic regions and in the appropriate season, donors and recipients may be screened for exposure to West Nile virus, Chagas disease, Zika virus, or other unique pathogens  (<a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p>Human T lymphotropic virus (HTLV)-1 may cause spastic paraparesis/myelopathy or adult T cell leukemia/lymphoma. HTLV-2, which is endemic in regions including the Caribbean and parts of Asia and Africa, is less clearly associated with these diseases and has been difficult to distinguish serologically from HTLV-1. As a result of the low rate of infection in the United States and poor testing options, mandatory screening for HTLV-1/-2 was discontinued in the United States in 2009 [<a href="#rid15">15</a>]. Rarely, donor-transmitted HTLV-1 infection has been identified with significant adverse outcomes in some individuals. HTLV-1 and -2 may be distinguished from one another using Western blot or nucleic acid testing. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'HIV, HTLV, and hepatitis viruses'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Vaccinations</span><span class="headingEndMark"> — </span>Prevention of infection through immunization is of paramount importance to the increasing population of solid organ transplant recipients [<a href="#rid13">13</a>]. Confirmation of vaccine status for hepatitis B virus, measles-mumps-rubella, hepatitis A virus, human papillomavirus, pneumococcus, and tetanus-diphtheria and pertussis, varicella zoster, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be obtained. Many immunocompromised patients are often unable to mount protective immune responses to vaccines. Live virus vaccines should be administered in advance of transplantation as immunosuppression may result in unchecked proliferation of attenuated vaccine strains and are generally avoided in solid organ transplant recipients. For these reasons, it is optimal to immunize patients prior to transplantation. Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Testing for latent tuberculosis</span><span class="headingEndMark"> — </span>The incidence of TB in solid organ transplant recipients is 20 to 74 times higher than in the general population [<a href="#rid16">16-21</a>]. The vast majority of cases are due to reactivation disease, although transmission via a transplanted organ has been described [<a href="#rid20">20,21</a>].</p><p>There are two available tests used to screen for latent TB infection (LTBI): the <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) and the interferon-gamma release assay (IGRA). Both tests are less sensitive in immunocompromised individuals. The frequency of indeterminate IGRAs is highest in liver transplant candidates. The IGRA is more often positive in renal transplant candidates than is the TST and has a greater association with risk factors for TB [<a href="#rid22">22-25</a>]. The predictive value in transplantation requires further study.</p><p>Radiographic changes on chest films can also be suggestive of prior exposure to TB.</p><p>Indications for prophylaxis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Untreated LTBI (eg, positive TST or IGRA without evidence of active TB) or LTBI without documentation of adequate therapy</strong></p><p class="bulletIndent1"><span class="glyph">●</span>A history of TB contact before transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Recipients of transplants from donors with a history of untreated TB</p><p></p><p>Patients who have completed a course of adequate therapy for TB do not need repeat prophylaxis unless they subsequently have one of the last two indications above. Therapy for latent TB should be initiated prior to transplantation but does not need to delay transplant.</p><p>Screening and treatment of latent TB in solid organ transplant candidates and recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Active infections in the transplant candidate</span><span class="headingEndMark"> — </span>Active bacterial and fungal infections must be eliminated or controlled, whenever possible, prior to transplantation. Even asymptomatic infections can evolve into overwhelming sepsis following transplantation. As an example, lung transplant candidates with cystic fibrosis will generally be colonized with organisms such as <em>P. aeruginosa</em>, <em>S.</em> <em>aureus</em>, and <em>B. cepacia </em>that are resistant to antimicrobial agents. Since manipulation of the infected lung tissue during transplantation might disseminate infection, perioperative bactericidal and fungicidal therapies are employed. <em>Burkholderia cenocepacia</em> appears to be a particularly virulent genomovar of <em>B. cepacia</em>. Management of lung transplant candidates and recipients who are colonized with this organism is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation", section on 'Burkholderia cepacia'</a>.)</p><p>Eradication of infection is often not feasible for colonized lungs, hepatic abscesses, or bile leaks. Infection must be controlled to the degree possible prior to transplant surgery. Proceeding to transplant in the setting of active infection requires thorough consideration of the risks and benefits of transplantation. Prior to, or at the time of "activation" of the candidate on the transplant waiting list, the status of any active or pertinent past infections should be documented, including plans for reimaging with interventional sampling to assure drainage of infected fluids or repeat respiratory cultures. </p><p>As noted above, patients with an anatomic predisposition to infections, such as cholecystitis, diverticulitis, or recurrent aspiration (in lung transplant recipients), may benefit from pre-emptive surgery prior to transplantation. Patients with a history of recurrent sinusitis should be evaluated prior to transplantation for sinus infection by computed tomography and by an otolaryngologist who can obtain culture specimens from deep tissue and/or perform a drainage procedure if needed. As an additional example, patients with recurrent <em>Clostridioides</em> <em>difficile </em>infection may benefit from fecal transplantation prior to solid organ transplantation [<a href="#rid26">26,27</a>].</p><p>Whenever possible, all intravenous or urinary catheters should be removed prior to transplantation. Exceptions include hemodialysis or peritoneal dialysis catheters in the nonbacteremic patient and intra-aortic balloon pumps or intravascular ventricular assist devices. These should be removed, if possible, at the time of transplantation. In patients with liver failure awaiting transplantation, elective intubation may be performed to prevent aspiration. Baseline sputum cultures should be obtained (to document colonizing organisms) and active infections treated when possible. Antimicrobial prophylaxis against spontaneous bacterial peritonitis, generally with a fluoroquinolone agent, may be useful in patients with ascites after documentation of negative cultures [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1248.html" rel="external">"Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis"</a>.)</p><p class="headingAnchor" id="H1797174670"><span class="h2">Coronavirus disease 2019</span><span class="headingEndMark"> — </span>Organ donors and recipients require careful assessment for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), prior to transplantation [<a href="#rid28">28,29</a>]. Immunosuppression is associated with more severe COVID-19 infection and, in the setting of steroid therapy, risk for bacterial and fungal superinfections. In addition, COVID-19 can induce a profound systemic inflammatory response, which could enhance the risk of graft rejection.</p><p class="bulletIndent1"><span class="glyph">●</span>Organ donors should be screened for COVID-19 prior to organ procurement. This is necessary for the safety of organ procurement teams as well as for the organ recipients. Protocols for screening deceased lung donors differ among institutions but often include screening from multiple sites. For example, screening by nasopharyngeal swab may be performed first and, if negative, followed by bronchoalveolar lavage sampling. (See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Donor screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All candidates for transplantation should be vaccinated against SARS-CoV-2 prior to transplantation. Efficacy of vaccination is significantly reduced with immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential organ recipients should be screened for COVID-19 prior to transplantation. Individuals with symptoms of respiratory viral illness should, in general, be deferred for transplantation. Asymptomatic individuals recovered from COVID-19 infection with negative testing have undergone successful transplantation. Some centers use quantitative polymerase chain reaction testing with low viral loads (ie, high cycle thresholds) on respiratory specimens ) in asymptomatic recipients as a basis for transplantability. (See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Candidate screening'</a>.)</p><p></p><p>Testing methods for COVID-19 are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Perioperative prophylaxis</span><span class="headingEndMark"> — </span>In the absence of specific data about colonization or infection due to resistant organisms in an individual patient, standard perioperative antimicrobial prophylaxis is administered for solid organ transplantation [<a href="#rid30">30</a>]. Regimens including <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (except in cardiac transplant recipients) or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> should be avoided whenever possible, to decrease the risk of colonization with vancomycin-resistant organisms and the latter to lessen the chance of developing diarrhea due to <em>C. difficile</em> postoperatively.</p><p>Generally, 24 hours or less of a first-generation cephalosporin provides adequate protection for renal transplantation in the absence of specific microbiologic data that would require broader coverage. In hepatic transplantation, coverage is generally employed for biliary and bowel flora including enterococci and anaerobic organisms, often in addition to antifungal prophylaxis. Perioperative antifungal prophylaxis with azole or echinocandin agents should be considered for patients with specific risk factors, including those requiring a Roux-en-Y loop, reoperation, and renal replacement therapy or for pancreas transplant recipients based upon the higher incidence of candidal infection in these hosts. Many centers with a significant rate of infection due to <em>Aspergillus</em> after liver or lung transplantation use perioperative prophylaxis with a lipid formulation of amphotericin B, inhaled amphotericin products (for lung transplant recipients), or later-generation azoles (<a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>). The azole antifungals have significant effects on the metabolism of calcineurin inhibitors and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>; dose adjustments must be made during and after such therapies [<a href="#rid31">31</a>].</p><p>More detailed recommendations for the use of perioperative prophylaxis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Peri-transplantation prophylaxis'</a>.)</p><p class="headingAnchor" id="H1480425298"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117424.html" rel="external">"Society guideline links: Infections in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H155046031"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important causes of infection</strong> – The organisms most commonly associated with post-transplant infection are the result of reactivation of latent infection carried by the donor organ or the recipient or are due to exposures in the community or in the hospital. (See <a class="local">'Causes of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent infections</strong> – Latent infection refers to organisms residing in tissues that is not causing active disease in the recipient or in the donor tissue. Cytomegalovirus, Epstein-Barr virus, <em>Toxoplasma gondii</em>, <em>Strongyloides stercoralis</em>, and <em>Trypanosoma cruzi</em> are examples of organisms that can exist in the normal host and are, in general, controlled by the host immune system. These pathogens may cause life-threatening infection in the immunocompromised host. The risk for reactivation of any latent infection is related to the nature and intensity of the immune suppression following transplantation. (See <a class="local">'Causes of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonizing organisms</strong> – Colonizing organisms may include antimicrobial-resistant organisms including methicillin-resistant <em>Staphylococcus aureus</em>, vancomycin-resistant enterococci, carbapenem-resistant <em>Klebsiella pneumoniae, Pseudomonas aeruginosa</em>, <em>Aspergillus</em> species, <em>Stenotrophomonas maltophilia</em>, and others. Multidrug-resistant organisms are important pathogens in transplantation. These organisms are potential pathogens in the setting of immunosuppression or acutely in the postoperative setting. (See <a class="local">'Causes of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplant evaluation</strong> – The pretransplant evaluation is central to the prevention of postoperative infection. The clinical evaluation of a patient prior to solid organ transplantation should focus on history of prior infections and relevant exposures, cultures for colonization, serologies for more distant exposures, and administration of vaccines. (See <a class="local">'Clinical evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History-taking</strong> – History-taking should be comprehensive and detailed to uncover exposures to organisms that may be of importance in the immunocompromised host (eg, travel and residence history, pets, occupational and recreational exposures, high-risk behaviors). In addition, a careful review of systems may uncover current occult infection or colonization. (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Laboratory testing for evidence of past infectious exposures is performed to detect asymptomatic infection in the transplant candidate. Some tests are suggested for all patients, whereas others are useful in selected patients with epidemiologic risk factors  (<a class="graphic graphic_table graphicRef59792" href="/z/d/graphic/59792.html" rel="external">table 1</a>). Serologic testing is used as an indicator of significant past exposures; screening for cytomegalovirus, herpes simplex virus, varicella zoster virus, hepatitis viruses, HIV, and toxoplasmosis are used as guides for prophylactic strategies after transplantation. (See <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of pretransplant vaccination</strong> – It is optimal to immunize patients prior to transplantation. Vaccine recommendations for solid organ transplant candidates and recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative prophylaxis</strong> – Perioperative antimicrobial prophylaxis is used to prevent infection in the early post-transplant period. (See <a class="local">'Perioperative prophylaxis'</a> above and  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Peri-transplantation prophylaxis'</a>.)</p><p></p><p class="headingAnchor" id="H1111083204"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017; 17:856.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.</a></li><li><a class="nounderline abstract_t">Malinis M, Boucher HW, AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13548.</a></li><li><a class="nounderline abstract_t">Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35:1513.</a></li><li><a class="nounderline abstract_t">Roberts MB, Fishman JA. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". Clin Infect Dis 2021; 73:e1302.</a></li><li><a class="nounderline abstract_t">Mularoni A, Bertani A, Vizzini G, et al. Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria. Am J Transplant 2015; 15:2674.</a></li><li><a class="nounderline abstract_t">Anesi JA, Blumberg EA, Han JH, et al. Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes. Transpl Infect Dis 2022; 24:e13783.</a></li><li><a class="nounderline abstract_t">Nellore A, Huprikar S, AST ID Community of Practice. Vancomycin-resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13549.</a></li><li><a class="nounderline abstract_t">Hand J, Patel G. Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections. Liver Transpl 2016; 22:1143.</a></li><li><a class="nounderline abstract_t">Aguado JM, Silva JT, Fernández-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando) 2018; 32:36.</a></li><li><a class="nounderline abstract_t">Fischer SA, Lu K, AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:9.</a></li><li><a class="nounderline abstract_t">Clemente WT, Pierrotti LC, Abdala E, et al. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. Transplantation 2018; 102:193.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13563.</a></li><li><a class="nounderline abstract_t">Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.</a></li><li class="breakAll">Guidance for HTLV-1 screening and confirmation in potential donors and reporting potential HTLV-1 infection. https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/guidance-for-htlv-1-screening-and-confirmation-in-potential-donors-and-reporting-potential-htlv-1-infection/ (Accessed on October 18, 2023).</li><li><a class="nounderline abstract_t">Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40:581.</a></li><li><a class="nounderline abstract_t">Aguado JM, Torre-Cisneros J, Fortún J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276.</a></li><li><a class="nounderline abstract_t">Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7:2797.</a></li><li><a class="nounderline abstract_t">Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012; 40:990.</a></li><li><a class="nounderline abstract_t">Epstein DJ, Subramanian AK. Prevention and Management of Tuberculosis in Solid Organ Transplant Recipients. Infect Dis Clin North Am 2018; 32:703.</a></li><li><a class="nounderline abstract_t">Subramanian AK, Theodoropoulos NM, Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant 2019; 33:e13513.</a></li><li><a class="nounderline abstract_t">Kim SH, Lee SO, Park IA, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010; 12:113.</a></li><li><a class="nounderline abstract_t">Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Rogerson TE, Chen S, Kok J, et al. Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis 2013; 61:33.</a></li><li><a class="nounderline abstract_t">Theodoropoulos N, Lanternier F, Rassiwala J, et al. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2012; 14:1.</a></li><li><a class="nounderline abstract_t">Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One 2015; 10:e0124483.</a></li><li><a class="nounderline abstract_t">Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 2014; 14:477.</a></li><li class="breakAll">American Society of Transplantation. 2019-nCoV (Coronavirus): FAQs for Organ Donation and Transplantation. https://www.myast.org/faqs-organ-transplantation (Accessed on October 18, 2023).</li><li class="breakAll">Guidance from the International Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. https://ishlt.org/covid-19-information (Accessed on October 18, 2023).</li><li><a class="nounderline abstract_t">Anesi JA, Blumberg EA, Abbo LM. Perioperative Antibiotic Prophylaxis to Prevent Surgical Site Infections in Solid Organ Transplantation. Transplantation 2018; 102:21.</a></li><li><a class="nounderline abstract_t">Husain S, Sole A, Alexander BD, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. J Heart Lung Transplant 2016; 35:261.</a></li></ol></div><div id="topicVersionRevision">Topic 1398 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117944" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infection in Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30900327" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12471571" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recipient screening prior to solid-organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32803228" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981339" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcome of Transplantation Using Organs From Donors Infected or Colonized With Carbapenem-Resistant Gram-Negative Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34968006" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30913322" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vancomycin-resistant Enterococcus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27228555" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28811074" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464994" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Screening of donor and recipient in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381647" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002409" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807271" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Strongyloidiasis in transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Strongyloidiasis in transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712081" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycobacterium tuberculosis infection in recipients of solid organ transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320593" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941955" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22496318" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146031" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevention and Management of Tuberculosis in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817030" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113458" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20577159" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23068425" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tests for latent tuberculosis in people with ESRD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883759" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25886133" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433460" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433460" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433460" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28614192" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Perioperative Antibiotic Prophylaxis to Prevent Surgical Site Infections in Solid Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970469" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
